RU2016121850A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016121850A3 RU2016121850A3 RU2016121850A RU2016121850A RU2016121850A3 RU 2016121850 A3 RU2016121850 A3 RU 2016121850A3 RU 2016121850 A RU2016121850 A RU 2016121850A RU 2016121850 A RU2016121850 A RU 2016121850A RU 2016121850 A3 RU2016121850 A3 RU 2016121850A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900946P | 2013-11-06 | 2013-11-06 | |
| US201361900919P | 2013-11-06 | 2013-11-06 | |
| US201361900878P | 2013-11-06 | 2013-11-06 | |
| US61/900,919 | 2013-11-06 | ||
| US61/900,946 | 2013-11-06 | ||
| US61/900,878 | 2013-11-06 | ||
| PCT/US2014/064441 WO2015069956A2 (en) | 2013-11-06 | 2014-11-06 | Novel formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016121850A RU2016121850A (ru) | 2017-12-08 |
| RU2016121850A3 true RU2016121850A3 (enExample) | 2018-08-08 |
| RU2691951C2 RU2691951C2 (ru) | 2019-06-19 |
Family
ID=53042097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016121850A RU2691951C2 (ru) | 2013-11-06 | 2014-11-06 | Новые составы |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US9949991B2 (enExample) |
| EP (3) | EP3065727B1 (enExample) |
| JP (4) | JP2016535787A (enExample) |
| KR (1) | KR20160079109A (enExample) |
| CN (3) | CN112370456A (enExample) |
| AU (2) | AU2014346682B2 (enExample) |
| CA (1) | CA2929821A1 (enExample) |
| ES (1) | ES2834131T3 (enExample) |
| HK (1) | HK1224228A1 (enExample) |
| IL (1) | IL245420B (enExample) |
| MX (2) | MX386250B (enExample) |
| RU (1) | RU2691951C2 (enExample) |
| SG (1) | SG11201604153UA (enExample) |
| WO (3) | WO2015069961A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169939A2 (en) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| CA2929821A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Inc. | 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate formulations and kits |
| KR20230173224A (ko) * | 2016-05-13 | 2023-12-26 | 에어로믹스, 인코포레이티드 | 결정 |
| JP2021023226A (ja) * | 2019-08-06 | 2021-02-22 | 学校法人慶應義塾 | アクアポリン活性調節剤候補のハイスループットスクリーニング方法 |
| CN110790787B (zh) * | 2019-11-12 | 2022-06-14 | 广东药科大学 | 一类水溶性前药、其制备方法及其作为药物的用途 |
| EP4192442A4 (en) * | 2020-08-05 | 2025-03-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising an aquaporin inhibiter and manufacturing process therefor |
| CN117105810B (zh) * | 2023-10-23 | 2024-02-09 | 中国农业大学 | 一种具有广谱抗菌活性的化合物及其抗菌组合物 |
| CN118178653B (zh) * | 2024-03-22 | 2026-02-06 | 山东第一医科大学附属省立医院(山东省立医院) | 跨膜水交换蛋白aqp4抑制剂在制备抗脑胶质瘤药物上的应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE615511A (enExample) | 1961-03-25 | |||
| NL292958A (enExample) | 1962-05-29 | 1900-01-01 | ||
| GB8809205D0 (en) | 1988-04-19 | 1988-05-25 | Nye P C G | Treatment of oedema |
| US5137871A (en) | 1989-07-28 | 1992-08-11 | Regents Of The University Of California | Treatment to reduce edema for brain and musculature injuries |
| DE4010536A1 (de) * | 1990-04-02 | 1991-10-10 | Boehringer Mannheim Gmbh | Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure |
| US5486530A (en) | 1991-04-27 | 1996-01-23 | Boehringer Mannheim Gmbh | Use of torasemide for the treatment of brain oedemas |
| DE4113820A1 (de) | 1991-04-27 | 1992-10-29 | Boehringer Mannheim Gmbh | Verwendung von torasemid zur behandlung von hirnoedemen |
| US5741671A (en) | 1991-12-12 | 1998-04-21 | The Johns Hopkins University | Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1) |
| US5858702A (en) | 1991-12-13 | 1999-01-12 | The Johns Hopkins University | Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5) |
| US5519035A (en) | 1993-07-02 | 1996-05-21 | Cornell Research Foundation, Inc. | Treatment of stroke or in anticipation of the occurrence of brain ischemia |
| US20060167110A1 (en) | 1995-01-13 | 2006-07-27 | Blume Cherly D | Methods for treating cerebrovascular disease by administering desmethylselegiline |
| EP0886471A4 (en) | 1996-11-18 | 2002-07-17 | Emisphere Tech Inc | METHODS AND COMPOSITIONS FOR INDUCING ORAL TOLERANCE IN MUZZLES |
| WO1999007382A1 (en) | 1997-08-06 | 1999-02-18 | Smithkline Beecham Corporation | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases |
| US5905090A (en) | 1998-04-29 | 1999-05-18 | Italfarmaco S.P.A. | Analogues of the active metabolite of leflunomide |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| US6500809B1 (en) | 1999-11-12 | 2002-12-31 | Neuron Therapeutics, Inc. | Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| ES2211460T3 (es) | 1999-12-10 | 2004-07-16 | Pfizer Inc. | Compuestos de 1,4-dihidropiridina sustituidos con un heteroalrilo de 5 miembros como antagonistas de la bradiquinina. |
| CN101849953B (zh) | 2000-12-18 | 2012-04-25 | 株式会社医药分子设计研究所 | 炎症性细胞因子产生游离抑制剂 |
| EP2438913B1 (en) | 2002-03-20 | 2020-05-06 | University of Maryland, Baltimore | A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling |
| US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| US20060019958A1 (en) | 2002-06-05 | 2006-01-26 | Susumu Muto | Immunity-related protein kinase inhibitors |
| WO2003103647A1 (ja) | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ａｐ−１及びｎｆａｔ活性化阻害剤 |
| JPWO2003103648A1 (ja) | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
| AU2003242118B2 (en) | 2002-06-06 | 2008-09-11 | Institute Of Medicinal Molecular Design, Inc | O-substituted hydroxyaryl derivatives |
| CN1658872B (zh) | 2002-06-06 | 2010-09-22 | 株式会社医药分子设计研究所 | 抗过敏药 |
| CA2488974A1 (en) | 2002-06-10 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of cancer |
| EP1535609A4 (en) | 2002-06-10 | 2009-01-07 | Inst Med Molecular Design Inc | Nf-kb activation inhibitors |
| EP1555018A4 (en) | 2002-06-11 | 2009-01-07 | Inst Med Molecular Design Inc | MEANS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| CA2492593A1 (en) | 2002-07-15 | 2004-01-22 | Myriad Genetics, Inc. | Compounds, compositions, and methods employing same |
| WO2004068928A2 (en) | 2003-02-06 | 2004-08-19 | Uutech Limited | Bradykinin b2 receptor antagonist peptide from amphibian skin |
| US20080125488A1 (en) | 2003-05-01 | 2008-05-29 | Leverve Xavier M | Lactate Containing Pharmaceutical Composition and Uses Thereof |
| KR20060054308A (ko) | 2003-07-16 | 2006-05-22 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 피부 색소침착의 치료제 |
| AU2004279855A1 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
| US8467876B2 (en) | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
| WO2005039556A1 (ja) | 2003-10-29 | 2005-05-06 | Institute Of Medicinal Molecular Design. Inc. | 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬 |
| EP1691817A2 (en) | 2003-12-02 | 2006-08-23 | Corgentech, Inc. | NF-kB OLIGONUCLEOTIDE DECOY MOLECULES |
| CA2580606A1 (en) | 2004-09-18 | 2006-03-30 | University Of Maryland, Baltimore | Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| CN101043891A (zh) | 2004-09-18 | 2007-09-26 | 巴尔的摩马里兰大学 | 靶向NCCa－ATP通道的治疗剂及其使用方法 |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| EP1835909A2 (en) | 2005-01-04 | 2007-09-26 | Novartis AG | Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation |
| TWI462745B (zh) | 2005-04-28 | 2014-12-01 | Takeda Pharmaceutical | 安定的乳化組成物 |
| WO2007084464A2 (en) | 2006-01-17 | 2007-07-26 | The University Of North Carolina At Chapel Hill | Water channel blockers and methods of use thereof |
| JP4273235B2 (ja) * | 2006-06-01 | 2009-06-03 | 国立大学法人 新潟大学 | アクアポリン４阻害薬 |
| KR20090016762A (ko) | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
| CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
| US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| EP2086329B1 (en) | 2006-10-26 | 2014-07-23 | The Arizona Board of Regents on behalf of the University of Arizona | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| US9316633B2 (en) | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| US20080171719A1 (en) | 2006-11-28 | 2008-07-17 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
| WO2008067382A2 (en) | 2006-11-28 | 2008-06-05 | Alcon Research, Ltd. | Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions |
| CA2674949A1 (en) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Targeting ncca-atp channel for organ protection following ischemic episode |
| CN101631859B (zh) | 2007-01-16 | 2017-10-13 | Ipintl有限责任公司 | 用于治疗代谢综合征的新组合物 |
| US20120183600A1 (en) | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
| WO2008098160A1 (en) | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
| BRPI0807918A2 (pt) | 2007-02-17 | 2017-05-16 | Harvard College | composições e método para preservação de tecido |
| WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| EP2167107B1 (en) | 2007-06-22 | 2016-12-14 | University of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| WO2009006555A2 (en) | 2007-07-02 | 2009-01-08 | Yu, Ming | Methods, composition, targets for combinational cancer treatments |
| US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
| AU2008314979A1 (en) | 2007-10-23 | 2009-04-30 | Institute Of Medicinal Molecular Design, Inc. | Inhibitor of PAI-1 production |
| CN101932308B (zh) | 2007-12-04 | 2014-11-05 | 治疗医药股份有限公司 | 改良的配制剂和用于冻干的方法及由此提供的冻干物 |
| GB0724340D0 (en) * | 2007-12-13 | 2008-01-30 | Univ Dundee | Novel Therapeutic Agents |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| WO2009139925A1 (en) | 2008-05-16 | 2009-11-19 | Panacea Pharmaceuticals, Inc. | Methods for the treatment of brain edema |
| EP2326318A4 (en) | 2008-09-16 | 2012-05-23 | Univ Maryland | SUR1 HEMMER FOR THERAPEUTIC PURPOSES |
| US20120010178A1 (en) | 2008-10-21 | 2012-01-12 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| GB0823366D0 (en) | 2008-12-22 | 2009-01-28 | Uni I Oslo | Synthesis |
| CA2749575C (en) | 2009-01-12 | 2016-05-03 | Versitech Limited | Compounds and uses thereof for treating inflammation and modulating immune responses |
| US20120039805A1 (en) | 2009-02-20 | 2012-02-16 | Pangea Biosciences, Inc. | Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample |
| CN102883742B (zh) | 2010-03-10 | 2014-09-24 | 佛罗里达大学研究基金会有限公司 | 用松弛素调节水孔蛋白 |
| KR20200054319A (ko) | 2010-07-19 | 2020-05-19 | 바이오젠 체사피크 엘엘씨 | 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법 |
| EP2598145A1 (en) * | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| US20110052678A1 (en) | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| WO2012125749A2 (en) | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| DK2717883T3 (en) | 2011-05-02 | 2017-04-24 | Stichting Vumc | PROTECTION AGAINST ENDOTELIAL BARRIER DYSFUNCTION BY INHIBITION OF THE TYROSINKINASE ABL RELATED GENES (ARG) |
| RU2461375C1 (ru) * | 2011-05-19 | 2012-09-20 | Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) | Способ комбинированного лечения больных местно-распространенным раком желудка |
| WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| US9452973B2 (en) | 2012-05-04 | 2016-09-27 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Modulators of the relaxin receptor 1 |
| WO2013169939A2 (en) * | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| WO2015037659A1 (ja) | 2013-09-13 | 2015-03-19 | 株式会社医薬分子設計研究所 | 水溶液製剤及びその製造方法 |
| CA2929821A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Inc. | 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate formulations and kits |
| JP6463580B2 (ja) | 2013-12-13 | 2019-02-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ |
| US20180042873A1 (en) | 2014-11-13 | 2018-02-15 | Aeromics, Inc. | Novel methods |
| ES2927482T3 (es) | 2015-05-29 | 2022-11-07 | Univ Maryland | Métodos para reducir o prevenir el daño de la íntima causado por la estimulación mecánica de las células endoteliales |
| IL258509B2 (en) | 2015-10-07 | 2023-04-01 | Biogen Chesapeake Llc | Methods for treating injuries or conditions related to edema in the central nervous system |
| KR20230173224A (ko) | 2016-05-13 | 2023-12-26 | 에어로믹스, 인코포레이티드 | 결정 |
| KR102646250B1 (ko) | 2016-07-29 | 2024-03-11 | 레메디 파마슈티칼즈, 인크. | Sur1-trpm4 통로 저해제를 이용하는 의학적 치료 방법 |
| EP4192442A4 (en) * | 2020-08-05 | 2025-03-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising an aquaporin inhibiter and manufacturing process therefor |
-
2014
- 2014-11-06 CA CA2929821A patent/CA2929821A1/en active Pending
- 2014-11-06 AU AU2014346682A patent/AU2014346682B2/en active Active
- 2014-11-06 WO PCT/US2014/064447 patent/WO2015069961A1/en not_active Ceased
- 2014-11-06 MX MX2016006012A patent/MX386250B/es unknown
- 2014-11-06 CN CN202011275350.0A patent/CN112370456A/zh active Pending
- 2014-11-06 EP EP14859359.3A patent/EP3065727B1/en active Active
- 2014-11-06 CN CN202011275472.XA patent/CN112402434A/zh active Pending
- 2014-11-06 EP EP14859943.4A patent/EP3065728A4/en not_active Withdrawn
- 2014-11-06 WO PCT/US2014/064441 patent/WO2015069956A2/en not_active Ceased
- 2014-11-06 KR KR1020167014998A patent/KR20160079109A/ko not_active Withdrawn
- 2014-11-06 SG SG11201604153UA patent/SG11201604153UA/en unknown
- 2014-11-06 JP JP2016552485A patent/JP2016535787A/ja not_active Ceased
- 2014-11-06 US US15/034,543 patent/US9949991B2/en active Active
- 2014-11-06 JP JP2016552486A patent/JP6535338B2/ja active Active
- 2014-11-06 EP EP14860390.5A patent/EP3065729A4/en active Pending
- 2014-11-06 RU RU2016121850A patent/RU2691951C2/ru active
- 2014-11-06 HK HK16112696.4A patent/HK1224228A1/zh unknown
- 2014-11-06 US US15/035,006 patent/US20160279155A1/en not_active Abandoned
- 2014-11-06 US US15/034,274 patent/US9827253B2/en active Active
- 2014-11-06 WO PCT/US2014/064432 patent/WO2015069948A1/en not_active Ceased
- 2014-11-06 ES ES14859359T patent/ES2834131T3/es active Active
- 2014-11-06 CN CN201480061066.XA patent/CN106163506A/zh active Pending
-
2016
- 2016-05-02 IL IL245420A patent/IL245420B/en active IP Right Grant
- 2016-05-06 MX MX2021008629A patent/MX2021008629A/es unknown
-
2017
- 2017-10-24 US US15/792,707 patent/US10258636B2/en active Active
-
2018
- 2018-12-31 US US16/236,817 patent/US10894055B2/en active Active
-
2019
- 2019-05-31 JP JP2019102367A patent/JP6957557B2/ja active Active
- 2019-10-28 US US16/665,333 patent/US11071744B2/en active Active
-
2020
- 2020-06-01 AU AU2020203697A patent/AU2020203697A1/en not_active Abandoned
- 2020-11-16 US US17/099,435 patent/US11801254B2/en active Active
-
2021
- 2021-06-16 US US17/304,201 patent/US12213987B2/en active Active
- 2021-10-06 JP JP2021164647A patent/JP2022003084A/ja active Pending
-
2023
- 2023-10-23 US US18/492,750 patent/US12496308B2/en active Active